NCT06435858View on ClinicalTrials.gov

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

October 31, 2025

Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG

Empagliflozin

Empagliflozin 10mg

DRUG

Placebo

Placebo capsule

Trial Locations (2)

7000

RECRUITING

Cantonal Hospital Graubuenden, Chur

8091

RECRUITING

University Hospital Zurich, Division of Nephrology, Zurich

All Listed Sponsors
collaborator

University of Zurich

OTHER

lead

Cantonal Hospital Graubuenden

OTHER